Mayo Clinic Laboratories > Gastroenterology > Autoimmune GI dysmotility

Autoimmune GI dysmotility

Improving patient outcomes with targeted antibody testing

Autoimmune gastrointestinal dysmotility (AGID) is a clinical and limited manifestation of autoimmune dysautonomia typically associated with syncope, neuropathy, and sweating problems, but may also involve chronic gastrointestinal dysmotility.

Autoimmune GI dysmotility Test menu

Autoimmune GI dysmotility Autoimmune GI dysmotility

Autoimmune GI dysmotility

Identifying gastrointestinal dysmotility as autoimmune-mediated is extremely important because patients treated with immunotherapy can see a dramatic improvement — going from persistent nausea, vomiting, and weight loss to feeling normal within a few weeks. Our algorithmic approach to AGID testing uses multiple methodologies to identify antibodies associated with the illness. Test results can direct a search for an underlying cancer and guide treatment selection.

Key testing

Advantages

  • Useful for investigating unexplained weight loss, early satiety, anorexia, nausea, vomiting, constipation, or diarrhea in a patient with past or family history of cancer or autoimmunity.
  • Can direct a focused search for cancer.
  • Can help differentiate AGID from the effects of chemotherapy.

Highlights

Autoimmune Gastrointestinal Dysmotility Evaluation [Test in Focus]

Divyanshu (Div), Dubey, M.B.B.S, gives an overview of the new Autoimmune Gastrointestinal Dysmotility Evaluation available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to previous testing approaches, and what clinical action can be taken due to the results of this testing.

Learn more
References
  1. Internal Mayo Clinic study of 23 patients.
INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.